TriSalus Life Sciences, Inc. Share Price
NASDAQ: TLSI | Micro CapTriSalus Life Sciences, Inc. Stock Performance
Open $5.36 | Prev. Close $5.59 | Circuit Range N/A |
Day Range $5.24 - $5.61 | Year Range $2.23 - $7.83 | Volume 8,467 |
Average Traded $5.41 |
TriSalus Life Sciences, Inc. Share Price Today
As of 11 August 2026, TriSalus Life Sciences, Inc.'s share price is $5.57. The stock opened at $5.36, compared to its previous close of $5.59. During today's trading session, TriSalus Life Sciences, Inc.'s share price traded between $5.24 and $5.61, with an average price of $5.43. Over the past 52 weeks, the stock has recorded a high of $7.83 and a low of $2.23. In terms of performance, TriSalus Life Sciences, Inc.'s share price has risen by 10.52% over the last six months and is up 7.01% on a year-on-year basis.
TriSalus Life Sciences, Inc. Share Price Chart
TriSalus Life Sciences, Inc. Stock Fundamentals & Key Indicators
Market Cap $211.09M | PE Ratio (TTM) -3.03 | Dividend Yield N/A |
EPS (TTM) $-1.84 | Revenue (TTM) $45.15M | Return On Equity (TTM) 115.85% |
Profit Margin -86.88% | Debt to Equity -2.04 | Quarterly Earnings Growth YoY -350.65% |
TriSalus Life Sciences, Inc. Quarterly Profit & Loss
All figures in USD
TriSalus Life Sciences, Inc. Annual Profit & Loss
All figures in USD
About TriSalus Life Sciences, Inc.
TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers. It offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial for treating locally advanced pancreatic cancer. The company is also developing nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma, intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and pancreatic cancer. It serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. The company was founded in 2009 and is headquartered in Westminster, Colorado.
TriSalus Life Sciences, Inc. Historical Returns
| Month | Open | Close | Change % |
|---|---|---|---|
Aug 2026 | $4.56 | $5.56 | +22.47% |
Jul 2026 | $4.53 | $4.54 | -0.33% |
Jun 2026 | $3.33 | $4.55 | +33.19% |
May 2026 | $4.34 | $3.42 | -20.56% |
Apr 2026 | $4.15 | $4.30 | +7.36% |
Mar 2026 | $5.02 | $4.01 | -20.44% |
Feb 2026 | $4.86 | $5.04 | +1.41% |
Jan 2026 | $6.95 | $4.97 | -28.59% |
Dec 2025 | $6.75 | $6.96 | +1.46% |
Nov 2025 | $4.66 | $6.86 | +45.03% |
Oct 2025 | $4.69 | $4.73 | +2.27% |
Sep 2025 | $5.25 | $4.63 | -11.14% |
TLSI Share Price FAQs
What is TriSalus Life Sciences, Inc. share price today?
What is the 52 week high and 52 week low of TriSalus Life Sciences, Inc. stock?
What is TLSI's market capitalisation today?
What is TLSI's net income for the last quarter?
What is the 5 year returns of TLSI?
What is the high & low stock price of TLSI today?
Can I buy TLSI shares in India?